Back to Cell Types

EM-2Homo sapiens (Human)Cancer cell line

Also known as: EM2

🤖 AI SummaryBased on 13 publications

Quick Overview

EM-2 is a human chronic myelogenous leukemia cell line derived from a Ph-positive patient, used in cancer research.

Detailed Summary

EM-2 is a Ph-positive chronic myelogenous leukemia (CML) cell line established from a patient with CML in blast crisis. It is characterized by the presence of multiple copies of the Philadelphia chromosome (Ph) and is widely used in research to study the molecular mechanisms of CML. The cell line has been extensively analyzed for its cytogenetic and molecular features, including the detection of BCR-ABL fusion genes and chromosomal abnormalities. EM-2 is known for its stability in culture and its utility in investigating the pathogenesis of CML and the effects of therapeutic interventions. It has been used in studies related to the role of the BCR-ABL fusion protein in leukemogenesis and in the development of targeted therapies.

Research Applications

Study of Philadelphia chromosome and BCR-ABL fusion genesInvestigation of chromosomal abnormalities in CMLAnalysis of leukemogenesis mechanismsDevelopment of targeted therapies for CML

Key Characteristics

Ph-positiveMultiple copies of Ph chromosomeExpresses BCR-ABL fusion proteinStable in cultureUsed for in vitro studies of CML

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1196
Species	Homo sapiens (Human)
Tissue Source	Bone marrow[UBERON:UBERON_0002371]

Donor Information

Age	5
Age Category	Pediatric
Sex	Female
Race	caucasian

Disease Information

Disease	Chronic myeloid leukemia
Lineage	Myeloid
Subtype	Chronic Myeloid Leukemia, BCR-ABL1+
OncoTree Code	CMLBCRABL1

DepMap Information

Source Type	DSMZ
Source ID	ACH-000295_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Gln (c.743G>A)	Unspecified	Somatic mutation acquired during proliferation	PubMed=20575032
Gene fusion	ABL1	BCR-ABL1, BCR-ABL	-	BCR exon 1 fused to ABL1 exon 2	PubMed=10576511, PubMed=10071072, PubMed=8751477

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,12

D13S317

9,12

D16S539

11,12

D18S51

13,15

D19S433

15,16

D21S11

30

D2S1338

22,24

D3S1358

14,16

D5S818

8,12

D7S820

10

D8S1179

14

FGA

21,22

Penta D

13,14

Penta E

7,16

TH01

9.3

TPOX

8,12

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.

Virgili A., Nacheva E.

Mol. Cytogenet. 3:15.1-15.12(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

p53 alterations in human leukemia-lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization?

Uphoff C.C.

Leukemia 14:198-206(2000).

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";

Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.

Leuk. Res. 23:1055-1060(1999).

Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.

Drexler H.G., MacLeod R.A.F., Uphoff C.C.

Leuk. Res. 23:207-215(1999).

Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.

Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985).

Ph positive CML cell lines.";

Keating A.

Baillieres Clin. Haematol. 1:1021-1029(1987).

Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3.

Raskind W.H., Disteche C.M., Keating A., Singer J.W.

Cancer Genet. Cytogenet. 25:271-284(1987).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).